

Trust.Worthy.

Oral Zofran® (ondansetron HCl) for prevention of chemotherapy-induced nausea and vomiting (CINV) on days 2-3 following moderately emetogenic chemotherapy



Send your patients home with an antiemetic care package.

Prescribe ZOFRAN ODT (Orally Disintegrating Tablets) for days 2-3. Because protection from nausea and vomiting shouldn't stop when the patient leaves the clinic.

Visit www.ZOFRAN.com

- Oral ZOFRAN is the only antiemetic FDA-approved for the prevention of CINV on days 2-3 following moderately emetogenic chemotherapy
- ZOFRAN ODT dissolve instantly on the tongue without liquid
- Simple BID dosing – one 8-mg tablet twice a day

Phenylketonurics: ZOFRAN ODT contain phenylalanine

The most commonly reported adverse events in patients receiving ZOFRAN in clinical trials were headache (5% to 27%), diarrhea (<1% to 16%), constipation (<1% to 9%), fever (<1% to 8%), and malaise/fatigue (0% to 13%).¹

Use of oral ZOFRAN on days 2-3 should be preceded by oral ZOFRAN 8 mg BID on day 1.

Please see brief summary of Prescribing Information on adjacent page.

Zofran ODT[®]
Orally Disintegrating Tablets

SATISFYING OUTCOMES

 GlaxoSmithKline